Bioprocessing Warms to Artificial Intelligence
Artificial intelligence (AI) is poised to transform the pharmaceutical industry. According to a 2017 report, AI solutions for drug discovery may generate revenues exceeding $4 billion dollars by 2024. Within the bioprocessing sector, AI is attracting interest because it promises to reduce costs and accelerate timelines.
“There’s a huge potential for using AI in manufacturing and bioprocessing,” explains Vimal Mehta, PhD, CEO and co-founder of BioXcel Therapeutics. “If you can start to use AI to optimize production processes or help upscale them, you can meet challenges we face today, such as how to scale up production of a vaccine for COVID-19.”
Read the rest at the source: Genetic Engineering & Biotechnology News